Skip to content

Total Revenue at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$246.09M+87.0%
Biogen logo
BiogenBIIB
$2.48B+1.9%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$268.06M+9.7%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$136M-2.2%
uniQure logo
uniQureQURE
$3.56M+127%
Precigen logo
PrecigenPGEN
$23.25M+1,634%

Other financials

Income statement

See full
Operating income-$43.5M-103%
Net income-$42.4M-97.0%
EPS (diluted)-$0.12-50.0%

Balance sheet

See full
Cash & equivalents$276.6M+137%
Total debt$68.6M+11.2%
Total equity$211.9M+285%
Total assets$300.4M+117%

Cash flow

See full
Operating cash flow-$40.9M-85.6%
CapEx$24.0K-93.7%
Free cash flow-$40.9M-82.6%

Valuation

See full
Market cap$1.97B+351%
Enterprise value$1.76B+368%
P/S263.9×+203×

Profitability

See full
Operating margin-1,774.4%+1,437pp
Net margin-1,738.4%+1,407pp
FCF margin-1,503.6%+621pp

Returns & leverage

See full
Return on equity-97.3%-27.3pp
Debt / equity0.3×-0.8×
Current ratio14×+8.7×

Where this comes from

Reported directly by Taysha Gene Therapies, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Taysha Gene Therapies, Inc.'s total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Taysha Gene Therapies, Inc.'s total revenue?
Taysha Gene Therapies, Inc. (TSHA) reported total revenue of $0 in Q1 2026.
How has Taysha Gene Therapies, Inc.'s total revenue changed year-over-year?
Taysha Gene Therapies, Inc.'s total revenue decreased by 100.0% year-over-year, from $2.3M to $0.
What is the long-term trend for Taysha Gene Therapies, Inc.'s total revenue?
Over 3 years (2022 to 2025), Taysha Gene Therapies, Inc.'s total revenue has grown at a 57.5% compound annual growth rate (CAGR), from $2.5M to $9.77M.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.